search
Back to results

Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline (SCD-WELL)

Primary Purpose

Cognitive Dysfunction

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Mindfulness weekly courses for 8 weeks
Health education weekly courses for 8 weeks
Sponsored by
Institut National de la Santé Et de la Recherche Médicale, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cognitive Dysfunction focused on measuring Subjective Cognitive Decline, Mental Health, Meditation, Health Education

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Aged ≥ 60 years
  • Meet the research criteria proposed by the international SCD-I working group for studies in SCD
  • Performance within the normal range on standardised cognitive tests according to agreed study-specific standards to rule out mild cognitive impairment (MCI) and dementia
  • Either referred to the memory clinic by a physician or who are self-referrals because of memory concerns (assessed by a positive response to the question 'Are you worried about your memory?')
  • Ability to provide informed consent in accordance with International Conference on Harmonization of Good Clinical Practice (GCP/ICH) guidelines and local regulations
  • State that they are available for the trial duration

Exclusion Criteria:

  • Presence of a major neurological or psychiatric disorder (including generalised anxiety, major depressive disorder, or an addiction to alcohol or drugs) according to ICD-10 and/or DSM 5 criteria
  • Under legal guardianship or incapacitation
  • History of cerebral disease (vascular, degenerative, physical malformation, tumor, or head trauma with loss of consciousness for more than an hour) which interferes with the aims of the study protocol
  • Presence of a chronic disease or acute unstable illness (respiratory, cardiovascular, digestive, renal, metabolic, hematologic, endocrine or infectious) which interferes with the aims of the study protocol
  • Current or recent medication that may interfere with cognitive action (psychotropic, systemic corticosteroid, anti-Parkinson's, or analgesic drugs). The interfering nature of the different treatments will be at the discretion of the investigating doctor.
  • Have regularly or intensively practiced meditation or comparable practices (yoga, Qi Gong, Alexander technique)

    • more than one day per week for more than six months consecutively over the last 10 years,
    • intensively (internship or retreat > five consecutive days) over the past 10 years,
    • more than 25 days of retreats (cumulatively) prior to the last 10 years.

Sites / Locations

  • The Clinical Research Memory Centre of Lyon (CMRR), department of the University Hospitals of Lyon - Hospices Civils de Lyon (HCL)
  • The Department of Psychiatry at University of Cologne (UKK)
  • The Consorci Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)
  • The Division of Psychiatry at University College London (UCL).

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Mindfulness intervention

Health education intervention

Arm Description

consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.

follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration. The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention.

Outcomes

Primary Outcome Measures

Mean change in anxiety after the intervention
(measured by the trait-STAI)

Secondary Outcome Measures

Mean change in anxiety from baseline to 24 weeks
measured by the trait-STAI
Change in depression by the Geriatric Depression Scale (GDS)
depression (Geriatric Depression Scale) : Range 0-15, higher scores indicate greater depressive symptoms.
Change in behavioural measures of compassion measured by the Self Compassion and Compassionate Love Scale questionnaires
Self Compassion: Range 12-60, higher scores indicate greater compassion. Compassionate Love Scale: Range 21-147, higher scores indicate greater compassion.
Change in cognitive function assessed by a composite score derived from neuropsychological tests.
The composite score will correspond to the mean of z-scores calculated from relevant test scores from the Mattis Dementia Rating Scale-2 (DRS-2), Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding, Rey Auditory Verbal Learning Test (RAVLT), Category Fluency (Animals). Higher z-scores correspond to better cognitive performance.
Subjective measures of sleep collected via the Pittsburg Sleep Quality Index questionnaire
collected via the Pittsburg Sleep Quality Index questionnaire: Range 0-21, higher scores indicate better sleep quality
Change in lifestyle as assessed by The Physical Activity Scale for the Elderly questionnaire
assessed by The Physical Activity Scale for the Elderly questionnaire: Range 0-873, higher scores indicate more physical activity
Change in quality of life assessed by the world health organization quality of life - brief questionnaire
WHOQOL-bref: Range 21-147, higher scores indicate better quality of life.
Mean change in blood-based biological markers of stress and Alzheimer's disease assessed by DNA methylation patterns and quantities of proteins - neurofilament light and tau
assessed by DNA methylation patterns and quantities of proteins - neurofilament light and tau

Full Information

First Posted
December 16, 2016
Last Updated
February 8, 2021
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT03005652
Brief Title
Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline
Acronym
SCD-WELL
Official Title
A Multicenter Randomized Superiority Study To Compare The Effects Of An 8-Weeks Mindfulness-based Intervention Versus Health Education Programme On Mental Health And Wellbeing In Individuals With Subjective Cognitive Decline
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
April 21, 2017 (Actual)
Primary Completion Date
September 18, 2018 (Actual)
Study Completion Date
September 18, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The European Commission Horizon 2020 programme has funded the SCD-WELL trial to investigate the efficacy of mindfulness-based training to reduce anxiety in individuals with Subjective Cognitive Decline (SCD), in comparison to an active comparison condition. It is increasingly recognized that most neuropathological processes start years before the onset of clinical Alzheimer's disease (AD). Hence, there is a growing urgency to target individuals in the earliest stages for intervention when neurodegeneration is still limited. Individuals clinically judged to have SCD, defined by subjectively experienced cognitive decline but normal performance on cognitive tests, are at increased risk for future cognitive decline and AD. These individuals with SCD currently have no established treatment options. Symptoms of anxiety have high prevalence in this population, and evidence from recent longitudinal research links anxiety with significantly accelerated cognitive decline in at risk individuals. Effectively reducing anxiety in this population may therefore not only relieve participants from burdensome symptoms, but may also slow cognitive decline and delay or prevent the onset of AD. The investigators chose to study the efficacy of a mindfulness-based intervention to reduce anxiety in this population because this type of intervention has been shown to reduce anxiety in a number of populations, including in older adults. Further, accumulating evidence indicates that intensive mindfulness training effectively down-regulates a number of other adverse psychological and biological risk factors for AD, such as stress, depression, insomnia, feelings of loneliness and social exclusion, and cardiovascular risk factors. These findings are relevant to AD because approximately a third of AD cases worldwide might be attributable to potentially modifiable risk factors. In spite of the increased use of mindfulness-based interventions to treat clinical symptoms, these trials often suffer from the lack of an adequate comparison condition and lack of follow up to know whether initial benefits are maintained.
Detailed Description
SCD-WELL includes both an active comparison condition and a 16-week follow up assessment after the end of the intervention. SCD-WELL is a non-CTIMP European multicentre, observer-blinded, randomized, controlled, superiority trial with two parallel groups, which compares anxiety and additional behavioural and biological outcomes amongst people with SCD who receive mindfulness-based training and those who receive a health education comparison intervention. Outcomes will be measured at baseline, post-intervention and 16 weeks after the end of the intervention. 160 older-adult patients diagnosed with SCD will be recruited to the study from memory clinics at four sites in Europe: London, UK; Cologne, Germany; Barcelona, Spain; Lyon, France where they will have sought help due to concern about their memory. Participants will be recruited in two waves over a maximum two-year period and will be provided with a participant information sheet, and asked to consider their participation. Should they wish to participate, and after a signed and dated Informed Consent Form has been obtained, a unique participant identification (ID) will be assigned to the participant. Behavioural assessments will take place at baseline, after the intervention, and 16 weeks after the end of the intervention. Because we believe that mindfulness-based training has the potential to affect a number of areas of life we will also look at changes in other areas of psycho-affective symptoms, social functioning, awareness, well being and quality of life, sleep quality, and cognition, after the intervention and 16 weeks after the end of the intervention. Validated neuropsychological tests and behavioural questionnaires were selected for their sensitivity to the domains listed above. These measures will be completed alone by the participant or in the presence of a psychometrist. Questionnaires will also be completed by partners at the three time points to coincide with assessments of participants. Blood samples will be taken at the memory clinic by certified phlebotomists at baseline, after the intervention and during follow-up to measure genetic markers of risk for AD as well as proteomic markers of stress and AD that may be affected by this intervention. Information will also be collected about the medical care of the participant. Trained facilitators will deliver both interventions. Both interventions follow a manual, are group-based, include at-home activities, and are 8 weeks in duration. Both interventions provide individuals with sustainable skills that remain beyond the intervention period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Dysfunction
Keywords
Subjective Cognitive Decline, Mental Health, Meditation, Health Education

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The trial will compare outcomes in two groups of participants randomised to one of two study arms, either receiving: (i) an 8-week mindfulness-based intervention, using a secular form of mindfulness training; or (ii) an 8-week validated health-educational programme (comparison condition, see section 6.3 for description) The randomization will be performed with a 1:1 allocation. The primary outcome will be change in symptoms of anxiety from baseline to 8 weeks.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
168 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mindfulness intervention
Arm Type
Experimental
Arm Description
consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.
Arm Title
Health education intervention
Arm Type
Active Comparator
Arm Description
follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration. The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention.
Intervention Type
Behavioral
Intervention Name(s)
Mindfulness weekly courses for 8 weeks
Intervention Description
The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
Intervention Type
Behavioral
Intervention Name(s)
Health education weekly courses for 8 weeks
Intervention Description
The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
Primary Outcome Measure Information:
Title
Mean change in anxiety after the intervention
Description
(measured by the trait-STAI)
Time Frame
Between baseline and the end of the 8-week interventions
Secondary Outcome Measure Information:
Title
Mean change in anxiety from baseline to 24 weeks
Description
measured by the trait-STAI
Time Frame
From baseline and 24 weeks
Title
Change in depression by the Geriatric Depression Scale (GDS)
Description
depression (Geriatric Depression Scale) : Range 0-15, higher scores indicate greater depressive symptoms.
Time Frame
a) from baseline to the end of the 8-week intervention b) from baseline to 24 weeks.
Title
Change in behavioural measures of compassion measured by the Self Compassion and Compassionate Love Scale questionnaires
Description
Self Compassion: Range 12-60, higher scores indicate greater compassion. Compassionate Love Scale: Range 21-147, higher scores indicate greater compassion.
Time Frame
a) from baseline to the end of the 8-week intervention b) from baseline to 24 weeks.
Title
Change in cognitive function assessed by a composite score derived from neuropsychological tests.
Description
The composite score will correspond to the mean of z-scores calculated from relevant test scores from the Mattis Dementia Rating Scale-2 (DRS-2), Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding, Rey Auditory Verbal Learning Test (RAVLT), Category Fluency (Animals). Higher z-scores correspond to better cognitive performance.
Time Frame
a) from baseline to the end of the 8-week intervention b) from baseline to 24 weeks.
Title
Subjective measures of sleep collected via the Pittsburg Sleep Quality Index questionnaire
Description
collected via the Pittsburg Sleep Quality Index questionnaire: Range 0-21, higher scores indicate better sleep quality
Time Frame
a) from baseline to the end of the 8-week intervention b) from baseline to 24 weeks.
Title
Change in lifestyle as assessed by The Physical Activity Scale for the Elderly questionnaire
Description
assessed by The Physical Activity Scale for the Elderly questionnaire: Range 0-873, higher scores indicate more physical activity
Time Frame
a) from baseline to the end of the 8-week intervention b) from baseline to 24 weeks.
Title
Change in quality of life assessed by the world health organization quality of life - brief questionnaire
Description
WHOQOL-bref: Range 21-147, higher scores indicate better quality of life.
Time Frame
a) from baseline to the end of the 8-week intervention b) from baseline to 24 weeks.
Title
Mean change in blood-based biological markers of stress and Alzheimer's disease assessed by DNA methylation patterns and quantities of proteins - neurofilament light and tau
Description
assessed by DNA methylation patterns and quantities of proteins - neurofilament light and tau
Time Frame
a) from baseline to the end of the 8-week interventions and b) from baseline to 24 weeks.
Other Pre-specified Outcome Measures:
Title
Difference in partner perceptions of participant mindfulness measured by Five-Facet Mindfulness Questionnaire (FFMQ-15, range 15-75, higher scores indicate greater mindfulness)
Description
Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant.
Time Frame
a) from baseline to the end of the 8-week intervention and b) from baseline to 24 weeks.
Title
Difference in partner perceptions of participant compassion towards others measured by Compassionate Love Scale (Range 21-147, higher scores indicate greater compassion)
Description
Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant.
Time Frame
a) from baseline to the end of the 8-week intervention and b) from baseline to 24 weeks.
Title
Difference in partner perceptions of participant depression measured by the Geriatric Depression Scale (range 0-15, higher scores indicate greater depressive symptoms)
Description
Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant.
Time Frame
a) from baseline to the end of the 8-week intervention and b) from baseline to 24 weeks.
Title
Difference in partner perceptions of participant anxiety measured by trait subscale of the state-trait anxiety inventory (trait-STAI, range 20-80, higher scores indicate greater anxiety symptoms)
Description
Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant.
Time Frame
a) from baseline to the end of the 8-week intervention and b) from baseline to 24 weeks.
Title
Difference in partner perceptions of participant prosocialness measured by Prosocialness scale (range 16-80, higher scores indicate greater prosocialness)
Description
Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant.
Time Frame
a) from baseline to the end of the 8-week intervention and b) from baseline to 24 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Aged ≥ 60 years Meet the research criteria proposed by the international SCD-I working group for studies in SCD Performance within the normal range on standardised cognitive tests according to agreed study-specific standards to rule out mild cognitive impairment (MCI) and dementia Either referred to the memory clinic by a physician or who are self-referrals because of memory concerns (assessed by a positive response to the question 'Are you worried about your memory?') Ability to provide informed consent in accordance with International Conference on Harmonization of Good Clinical Practice (GCP/ICH) guidelines and local regulations State that they are available for the trial duration Exclusion Criteria: Presence of a major neurological or psychiatric disorder (including generalised anxiety, major depressive disorder, or an addiction to alcohol or drugs) according to ICD-10 and/or DSM 5 criteria Under legal guardianship or incapacitation History of cerebral disease (vascular, degenerative, physical malformation, tumor, or head trauma with loss of consciousness for more than an hour) which interferes with the aims of the study protocol Presence of a chronic disease or acute unstable illness (respiratory, cardiovascular, digestive, renal, metabolic, hematologic, endocrine or infectious) which interferes with the aims of the study protocol Current or recent medication that may interfere with cognitive action (psychotropic, systemic corticosteroid, anti-Parkinson's, or analgesic drugs). The interfering nature of the different treatments will be at the discretion of the investigating doctor. Have regularly or intensively practiced meditation or comparable practices (yoga, Qi Gong, Alexander technique) more than one day per week for more than six months consecutively over the last 10 years, intensively (internship or retreat > five consecutive days) over the past 10 years, more than 25 days of retreats (cumulatively) prior to the last 10 years.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank Jessen
Organizational Affiliation
Director of the Clinic for Psychiatry and Psychotherapy at University Hospital Cologne
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Natalie Marchant
Organizational Affiliation
Division of Psychiatry, University College London
Official's Role
Study Director
Facility Information:
Facility Name
The Clinical Research Memory Centre of Lyon (CMRR), department of the University Hospitals of Lyon - Hospices Civils de Lyon (HCL)
City
Lyon
Country
France
Facility Name
The Department of Psychiatry at University of Cologne (UKK)
City
Cologne
Country
Germany
Facility Name
The Consorci Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)
City
Barcelona
Country
Spain
Facility Name
The Division of Psychiatry at University College London (UCL).
City
London
State/Province
England
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36068621
Citation
Whitfield T, Demnitz-King H, Schlosser M, Barnhofer T, Frison E, Coll-Padros N, Dautricourt S, Requier F, Delarue M, Gonneaud J, Klimecki OM, Lutz A, Paly L, Salmon E, Schild AK, Walker Z, Jessen F, Chetelat G, Collette F, Wirth M, Marchant NL; Medit-Ageing Research Group. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial. Alzheimers Res Ther. 2022 Sep 6;14(1):125. doi: 10.1186/s13195-022-01057-w.
Results Reference
derived
PubMed Identifier
35853750
Citation
Demnitz-King H, Gonneaud J, Klimecki OM, Chocat A, Collette F, Dautricourt S, Jessen F, Krolak-Salmon P, Lutz A, Morse RM, Molinuevo JL, Poisnel G, Touron E, Wirth M, Walker Z, Chetelat G, Marchant NL; Medit-Ageing Research Group. Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults. Neurology. 2022 Sep 27;99(13):e1422-e1431. doi: 10.1212/WNL.0000000000200951. Epub 2022 Jul 19.
Results Reference
derived
PubMed Identifier
33873195
Citation
Marchant NL, Barnhofer T, Coueron R, Wirth M, Lutz A, Arenaza-Urquijo EM, Collette F, Poisnel G, Demnitz-King H, Schild AK, Coll-Padros N, Delphin-Combe F, Whitfield T, Schlosser M, Gonneaud J, Asselineau J, Walker Z, Krolak-Salmon P, Molinuevo JL, Frison E, Chetelat G, Jessen F, Klimecki OM; The Medit-Ageing Research Group. Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychother Psychosom. 2021;90(5):341-350. doi: 10.1159/000515669. Epub 2021 Apr 19.
Results Reference
derived

Learn more about this trial

Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline

We'll reach out to this number within 24 hrs